tumor proliferation
Recently Published Documents





2022 ◽  
Vol 2022 ◽  
pp. 1-11
Zhiqun Bai ◽  
Xuemei Wang ◽  
Zhen Zhang

Emerging evidence has indicated that aberrantly expressed long noncoding RNAs (lncRNAs) play a vital role in various biological processes associated with tumorigenesis. Leukemia inhibitory factor receptor antisense RNA1 (LIFR-AS1) is a recently identified lncRNA transcribed in an antisense manner from the LIFR gene located on human chromosome 5p13.1. LIFR-AS1 regulates tumor proliferation, migration, invasion, apoptosis, and drug resistance through different mechanisms. Its expression level is related to the clinicopathological characteristics of tumors and plays a key role in tumor occurrence and development. In this review, we summarize the role of LIFR-AS1 in the development and progression of different cancers and highlight the potential for LIFR-AS1 to serve as a biomarker and therapeutic target for a variety of human cancers.

2022 ◽  
Vol 18 (2) ◽  
pp. 522-535
Zhencong Chen ◽  
Zhengyang Hu ◽  
Qihai Sui ◽  
Yiwei Huang ◽  
Mengnan Zhao ◽  

2021 ◽  
Jin Zhang ◽  
Biyu Cai ◽  
Chenxiao Ye ◽  
Xinrong Li ◽  
Haitao Chen ◽  

Abstract Background. With the increasing incidence of breast cancer and the integration of multiple methods in the treatment, traditional Chinese medicine plays an increasingly important role in the comprehensive treatment of breast cancer. we aimed to determine the anti-cancer metastasis effect of Jianpi Tiaoqi Decoction (JPTQ) on breast cancer-bearing mice by monitoring the effects of its on tumor proliferation, apoptosis, angiogenesis, epithelial to mesenchymal transition (EMT) process and regulation of immune microenvironment. Methods. The general phenotype of the Cancer-bearing mice was monitored. Bioluminescence-imaging was performed to assess the tumor status and the metastatic status of other organs. We investigated its mechanism of the effect through transcriptome analysis, Flow Cytometry(FCM) was used to analyze peripheralblood CD4+ T cells, spleen T helper 1 (Th1) cell, the proportion of MDSCs in lung. The changes of EMT process, vascular endothelial growth factor (VEGF) and Ki-67, Caspase-3 and Bcl-2 were detected by quantitative real time polymerase chain reaction (q-PCR), western blot (WB) or immunohistochemistry (IHC). Results. JPTQ inhibited the tumors proliferation and reduced lung metastasis. The transcriptome analysis of lung and tumor tissues indicated that EMT-related genes, angiogenesis, proliferation and apoptosis genes were regulated in JPTQ group, and the Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis observed enrichment of immune-related pathways. FCM suggested that JPTQ could reduced the proportion of M-MDSCs in the lung, and increased peripheral blood CD4+ T cells and Th1 cells in spleen. The q-PCR, WB or IHC assay demonstrated that E-cadherin was up-regulated in lung and tumor tissue, and Snail was down-regulated, the expression of matrix metalloprotein-9(MMP-9)was down-regulated in lung tissue. IHC showed the down-regulation of Ki67 and VEGF in lung and tumo tissues. WB found that Cleved-Caspase3 was significantly up-regulated, while Bcl-2 was down-regulated. Conclution. JPTQ can inhibit proliferation, angiogenesis, promote apoptosis and improve the immune microenvironment, and reverse the EMT process to inhibit the proliferation and metastasis of TNBC.

2021 ◽  
Vol 11 ◽  
Qianqian Zhang ◽  
Xiaohong Deng ◽  
Xiuxin Tang ◽  
Ying You ◽  
Meihua Mei ◽  

PurposeHepatocellular carcinoma (HCC), a worldwide leading cause of morbidity and mortality, is the most frequent primary liver tumor. Most HCC patients are diagnosed with advanced liver cancer, resulting in a very low 5-year survival rate. Thus, there is an urgent need for the development of targeted therapies. In this study, we aimed to investigate the effect and mechanism of the miR-20a/EZH1 axis on the proliferation and metastasis of HCC and the inhibitory effect of the EZH1/EZH2 inhibitor UNC1999 on HCC.Materials and MethodsThe expression of miR-20a in human HCC tissues and cell lines was detected using quantitative real-time PCR (qRT-PCR). The expressions of proteins were analyzed with immunohistochemistry and Western blotting. Luciferase assay was used to verify whether miR-20a targets EZH1 or EZH2. The effect of miR-20a on HCC progression was studied in vivo and in vitro. The tumor inhibitory effect of UNC1999 was confirmed in vivo. CCK8 assay, wound healing assay, cell migration and invasion assay were used to evaluate the synergistic effect of UNC1999 with sorafenib. RNA sequencing (RNA-seq) was performed to screen the differentially expressed genes in the Huh7 and SMMC7721 cell lines after UNC1999, sorafenib, and combination treatments.ResultsIn this study, miR-20a showed a lower expression in both HCC tissues and cell lines. MiR-20a inhibited the proliferation and migration of SMMC7721 and Huh7 cells. The results of the luciferase assay and Western blot analysis revealed that miR-20a directly targeted EZH1, a histone methyltransferase. We demonstrated that miR-20a negatively regulated the expression of EZH1 and inhibited the proliferation and metastasis of HCC by reducing H3K27 methylation. We found UNC1999 inhibited tumor cells proliferation and enhanced the inhibitory effect of sorafenib.ConclusionWe demonstrated that miR-20a suppresses the tumor proliferation and metastasis in HCC by directly targeting EZH1. UNC1999 can inhibit tumor proliferation in vivo and increase the sensitivity of hepatoma cell lines to sorafenib.

2021 ◽  
Vol 11 ◽  
Fabian Acker ◽  
Jan Stratmann ◽  
Lukas Aspacher ◽  
Ngoc Thien Thu Nguyen ◽  
Sebastian Wagner ◽  

KRAS is one of the most commonly mutated oncogenes in cancer, enabling tumor proliferation and maintenance. After various approaches to target KRAS have failed over the past decades, the first specific inhibitor of the p.G12C mutation of KRAS was recently approved by the FDA after showing promising results in adenocarcinomas of the lung and other solid tumors. Lung cancer, the most common cancer worldwide, is a promising use case for these new therapies, as adenocarcinomas in particular frequently harbor KRAS mutations. However, in squamous cell carcinoma (SCC) of the lung, KRAS mutations are rare and their impact on clinical outcome is poorly understood. In this review, we discuss the current knowledge on the prevalence and prognostic and predictive significance of KRAS mutations in the context of SCC.

2021 ◽  
Vol 2021 ◽  
pp. 1-11
Han-chuan Tao ◽  
Cheng Wang ◽  
Ning Ma ◽  
Xun Zhu ◽  
Xiao-jun Zhou

Superenhancer usages in single cancer form such as colorectal cancer (CRC) may provide novel efficient targeting candidates. It is unclear whether CRC contains recurrent superenhancers that confer a predisposition to malignancy. We investigated the superenhancer profile of CRC cell line HCT116 and compared it to that of a healthy sigmoid colon. We found that HCT116 had lost most of the normal colon superenhancer activities but gained a new set of tumor-favoring superenhancers that facilitate tumor proliferation, growth signalling, and hypoxia resistance. Inhibiting the superenhancers by JQ-1 treatment had significantly decreased the colony formation capability of HCT116. Then, by comparing the superenhancer genes and robust CRC upregulated genes, we identified a superenhancer associated with a common CRC upregulated oncogene, POU5f1B. POU5f1B overexpression is related to the worse outcome in CRCs. Via performing ChIP-PCR in 35 clinical samples and investigating CRC anti-H3K27ac ChiP-seq public dataset consisting of 36 samples, we further identified that the superenhancer of oncogene POU5F1B is recurrently activated in CRCs, taking 62 and 72 per cent, respectively. Moreover, JQ-1 treatment successfully inhibited the POU5F1B expression in 5 out of 6 POU5F1B superenhancer-positive samples. Therefore, we concluded that the superenhancer activation of POU5F1B contributes partially to its high expression in CRCs, in addition to the well-known gene amplification aetiology.

2021 ◽  
Vol 3 (Supplement_6) ◽  
pp. vi5-vi6
Shintaro Yamazaki ◽  
Fumiharu Ohka ◽  
Masaki Hirano ◽  
Yukihiro Shiraki ◽  
Kazuya Motomura ◽  

Abstract Recent comprehensive studies have revealed several molecular alterations that are frequently found in meningiomas. However, effective treatment reagents targeting specific molecular alterations have not yet been identified because of the limited number of representative research models of meningiomas. We established 18 organoid models comprising of two malignant meningioma cells (HKBMM and IOMM-Lee), 10 benign meningiomas, four malignant meningiomas, and two solitary fibrous tumors (SFTs). Using immunohistochemistry and molecular analyses consisting of whole exome sequencing, RNA-seq, and DNA methylation analyses, we compared the histological findings and molecular profiling of organoid models with those of parental tumors. The organoids exhibited consistent histological features and molecular profiles with those of the parental tumors. Using a public database of meningioma, we identified that upregulated forkhead box M1 (FOXM1) was correlated with increased tumor proliferation. Overexpression of FOXM1 in benign meningioma organoids increased organoid proliferation; depletion of FOXM1 in malignant organoids decreased proliferation. Additionally, thiostrepton, a FOXM1 inhibitor combined with radiation therapy, significantly inhibited proliferation of malignant meningioma organoid models (P<0.01). An organoid model for meningioma enabled us to elucidate the tumor biology of meningioma along with potent treatment targets for meningioma.

Sign in / Sign up

Export Citation Format

Share Document